NCT03897075

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: Sun Pharmaceutical Industries Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis

Conditions

• Chronic Plaque Psoriasis
• Moderate to Severe Nail Psoriasis

Interventions

Type	Name	Description
DRUG	Tildrakizumab	PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
DRUG	Placebo	PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up

Timeline

• Start date: 2021-05-13
• Primary completion: 2024-04-05
• Completion: 2025-01-30
• First posted: 2019-04-01
• Last updated: 2026-04-01
• Results posted: 2025-06-06

Locations

17 sites across 2 countries: United States, Australia

Regulatory

• FDA-regulated drug study